Latest News on Peyronie’s Disease

FDA delayed the action on XIAFLEX® (collagenase clostridium histolyticum) for the treatment of Peyronie’s disease (“PD”) from September 6, 2013 to December 6, 2013 in order to examine newly submitted information from the manufacturer.

It is expected that the FDA will approve Xiaflex for Peyronie’s disease based on the lack of other approved treatments, demonstrable benefits and relative safety.